Gulley JL - Search Results

1

Immunotherapy in genitourinary malignancies.

Wattenberg MM, Fong L, Madan RA, Gulley JL. Wattenberg MM, et al. Among authors: gulley jl. Curr Opin Urol. 2016 Nov;26(6):501-7. doi: 10.1097/MOU.0000000000000331. Curr Opin Urol. 2016. PMID: 27471994 Free PMC article. Review.

2

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.

Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL. Figg WD, et al. J Urol. 2005 Mar;173(3):790-6. doi: 10.1097/01.ju.0000147013.09157.8e. J Urol. 2005. PMID: 15711271 Clinical Trial.

3

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.

Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W. Arlen PM, et al. Among authors: gulley jl. J Urol. 2005 Aug;174(2):539-46. doi: 10.1097/01.ju.0000165159.33772.5b. J Urol. 2005. PMID: 16006888 Clinical Trial.

4

PSA-based vaccines for the treatment of prostate cancer.

Madan RA, Gulley JL, Arlen PM. Madan RA, et al. Among authors: gulley jl. Expert Rev Vaccines. 2006 Apr;5(2):199-209. doi: 10.1586/14760584.5.2.199. Expert Rev Vaccines. 2006. PMID: 16608420 Review.

5

Immunotherapy for prostate cancer: what's the future?

Arlen PM, Dahut WL, Gulley JL. Arlen PM, et al. Among authors: gulley jl. Hematol Oncol Clin North Am. 2006 Aug;20(4):965-83, xi. doi: 10.1016/j.hoc.2006.03.003. Hematol Oncol Clin North Am. 2006. PMID: 16861126 Review.

6

PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.

Madan RA, Arlen PM, Gulley JL. Madan RA, et al. Among authors: gulley jl. Expert Opin Biol Ther. 2007 Apr;7(4):543-54. doi: 10.1517/14712598.7.4.543. Expert Opin Biol Ther. 2007. PMID: 17373905 Review.

7

Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.

Madan RA, Lieberman R, Gulley JL, Dahut W, Arlen PM. Madan RA, et al. Among authors: gulley jl. Am J Ther. 2007 May-Jun;14(3):310-3. doi: 10.1097/01.pap.0000249955.77460.f4. Am J Ther. 2007. PMID: 17515709

8

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.

Aragon-Ching JB, Williams KM, Gulley JL. Aragon-Ching JB, et al. Among authors: gulley jl. Front Biosci. 2007 Sep 1;12:4957-71. doi: 10.2741/2441. Front Biosci. 2007. PMID: 17569623 Review.

9

Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Gulley JL, Madan RA, Arlen PM. Gulley JL, et al. Vaccine. 2007 Sep 27;25 Suppl 2(Suppl 2):B89-96. doi: 10.1016/j.vaccine.2007.04.091. Epub 2007 Jun 4. Vaccine. 2007. PMID: 17573164 Free PMC article. Review.

10

Clinical safety of a viral vector based prostate cancer vaccine strategy.

Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Arlen PM, et al. Among authors: gulley jl. J Urol. 2007 Oct;178(4 Pt 1):1515-20. doi: 10.1016/j.juro.2007.05.117. Epub 2007 Aug 16. J Urol. 2007. PMID: 17707059 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page